Besides this key mechanism of action, nonimmunological CNS mechanisms for fingolimod efficacy in multiple sclerosis therapy were identified that implicate S1P1 signaling in astrocytes as a key mediator, thus highlighting S1P signaling pathways within the CNS as targets for multiple sclerosis therapies (Choi et al., 2011). This evidence concerns the gene S1PR1 and multiple sclerosis.